International Urology and Nephrology

, Volume 50, Issue 4, pp 771–777 | Cite as

Impact of low-dose steroids on HbA1c levels and development of pre-diabetes and NODAT in non-diabetic renal transplant recipients on long-term follow-up

  • F. P. Tillmann
  • M. Schmitz
  • L. C. Rump
  • I. Quack
Nephrology - Original Paper

Abstract

Background

This study aimed to evaluate the impact of 5 mg of prednisolone/day on HbA1c levels and its association with the development of pre-diabetes and new-onset diabetes mellitus (NODAT) in non-diabetic first renal transplant recipients on long-term follow-up.

Methods

Four hundred patients were analysed on an average of 4.1 ± 3.0 years after successful transplantation: 96 (24%) were steroid-free and 304 (76%) treated with 5 mg of prednisolone/day combined with cyclosporine A (CsA) or tacrolimus (Tac) as part of their immunosuppressive protocol. Pre-diabetes and NODAT were defined based on the HbA1c levels according to the current ADA guidelines. The Mann–Whitney U test and the Chi-square test were used to determine intergroup differences. Multivariate logistic regression analyses (adjusted for steroid-free versus 5 mg of prednisolone per day, body mass index (BMI), number of HLA mismatches, eGFR according to the CKD-EPI formula, sex, negative vs. positive PRA titre, CMV and HCV positivity of the recipient, CsA vs. Tac immunosuppressive medication, dialysis vintage (years), age at the last follow-up and time from transplantation to the last follow-up) were performed to identify an independent effect of low-dose steroids on the evolution of pre-diabetes and NODAT.

Results

A small but statistically significant difference in HbA1c levels was observed between the control and the steroid groups (5.56 ± 0.54 vs. 5.67 ± 0.0.45%, p = 0.045). The incidence rates of pre-diabetes and NODAT per 100 patients per year were 9.3 and 3.0, respectively. Regression analysis showed that low-dose steroids (p = 0.026, risk ratio (RR) 1.789, 95%; confidence interval (CI) 1.007–3.040) and age (p = 0.000, RR 1.037/year, 95% CI 1.018–1.057) were associated with pre-diabetes, whereas BMI (p = 0.000, RR 1.190, 95% CI 1.084–1.307), age (p = 0.000, RR 1.087/year, 95% CI 1.047–1.129) and Tac use (p = 0.010, RR 3.300, 95% CI 1.328–8.196) were associated with NODAT.

Conclusion

Using 5 mg of prednisolone/day was associated with increased HbA1c levels and an increased risk in developing pre-diabetes, but not NODAT, whereas BMI, age and the use of tacrolimus were associated with an increased risk in developing NODAT.

Keywords

Renal transplantation Steroids Pre-diabetes NODAT Ageing HbA1c 

Notes

Author’s contributions

FPT designed the study, performed the statistical analyses and drafted the manuscript. IQ performed the data acquisition, conceived the study and helped in drafting the manuscript. LCR conceived the study, participated in its design and coordination and helped in drafting the manuscript. All authors have read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Boots JM, Christiaans MH, van Hooff JP (2004) Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 64:2047–2073CrossRefPubMedGoogle Scholar
  2. 2.
    Poetker DM, Reh DD (2010) A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin NY Am 43:753–768CrossRefGoogle Scholar
  3. 3.
    Knight SR, Morris PJ (2010) Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 89:1–14CrossRefPubMedGoogle Scholar
  4. 4.
    Vincenti F, Schena FP, Paraskevas S et al (2008) A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8:307–316CrossRefPubMedGoogle Scholar
  5. 5.
    Knight SR, Morris PJ (2011) Interaction between maintenance steroid dose and the risk/benefit of steroid avoidance and withdrawal regimens following renal transplantation. Transplantation 92:e63–e64CrossRefPubMedGoogle Scholar
  6. 6.
    Haller MC, Royuela A, Nagler EV et al (2016) Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD005632.pub3 PubMedGoogle Scholar
  7. 7.
    Tillmann FP, Quack I, Schenk A, Grabensee B, Rump LC, Hetzel GR (2012) Prevalence and risk factors of pre-diabetes after renal transplantation: a single-centre cohort study in 200 consecutive patients. Nephrol Dial Transplant 27:3330–3337CrossRefPubMedGoogle Scholar
  8. 8.
    Collins AJ, Foley RN, Herzog C et al (2011) US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 57(1Suppl 1):A8CrossRefPubMedGoogle Scholar
  9. 9.
    Kahwaji J, Bunnapradist S, Hsu JW, Idroos ML, Dudek R (2011) Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation 91:225–230CrossRefPubMedGoogle Scholar
  10. 10.
    Pascual J, Royuela A, Galeano C, Crespo M, Zamora J (2012) Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 27:825–832CrossRefPubMedGoogle Scholar
  11. 11.
    Opelz G, Doehler B, Laux G, for the Collaborative Transplant Study et al (2005) Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5:720–728CrossRefPubMedGoogle Scholar
  12. 12.
    Opelz G, Döhler B (2013) Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant 13:2096–2105CrossRefPubMedGoogle Scholar
  13. 13.
    Engberg H, Wehberg S, Bistrup C, Heaf J, Sørensen SS, Thiesson HC, Hansen JM, Svensson M, Green A, Marckmann P (2016) Cancer risk and mortality after kidney transplantation: a population-based study on differences between Danish centres using standard immunosuppression with and without glucocorticoids. Nephrol Dial Transplant 31:2149–2156CrossRefPubMedGoogle Scholar
  14. 14.
    Luan FL, Steffick DE, Ojo AO (2009) Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int 76:825–830CrossRefPubMedGoogle Scholar
  15. 15.
    Rike AH, Mogilishetty G, Alloway RR et al (2008) Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 22:229–235CrossRefPubMedGoogle Scholar
  16. 16.
    Huscher D, Thiele K, Gromnica-Ihle E et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119CrossRefPubMedGoogle Scholar
  17. 17.
    Da Silva JA, Jacobs JW, Kirwan JR et al (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65:285CrossRefPubMedGoogle Scholar
  18. 18.
    Schäcke H, Döcke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23CrossRefPubMedGoogle Scholar
  19. 19.
    Pani LN, Korenda L, Meigs JB et al (2008) Effect of aging on A1C levels in individuals without diabetes. Diabetes Care 31:1991–1996CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tillmann FP, Hermsen D, Hemmrich K, Woznowski M, Rump LC, Quack I (2015) Long-term effect of renal transplantation and aging on hemoglobin A1C levels: a case-control study in 191 non-diabetic deceased donor renal transplant recipients. Ann Transplant 20:729–733CrossRefPubMedGoogle Scholar
  21. 21.
    Hjelmesaeth J, Hartmann A, Leivestad T et al (2006) The impact of early diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69:588–595CrossRefPubMedGoogle Scholar
  22. 22.
    Shah T, Kasravi A, Huang E et al (2006) Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 82:1673–1676CrossRefPubMedGoogle Scholar
  23. 23.
    Moore R, Ravindran V, Baboolal K (2006) The burden of new-onset diabetes mellitus after transplantation. Clin Transplant 20:755–761CrossRefPubMedGoogle Scholar
  24. 24.
    Araki M, Flechner SM, Ismail HR et al (2006) Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 81:335–341CrossRefPubMedGoogle Scholar
  25. 25.
    Numakura K, Satoh S, Tsuchiya N et al (2005) Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 80:1419–1424CrossRefPubMedGoogle Scholar
  26. 26.
    Joss N, Staatz CE, Thomson AH et al (2007) Predictors of new onset diabetes after renal transplantation. Clin Transplant 21:136–143CrossRefPubMedGoogle Scholar
  27. 27.
    Bergenstal RM, Gal RL, Connor CG et al (2017) Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 167:95–102CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2017

Authors and Affiliations

  1. 1.Klinik für NephrologieHeinrich Heine Universität DüsseldorfDüsseldorfGermany
  2. 2.Klinik für Nephrologie und allgemeine innere Medizinstädtisches Klinikum SolingenSolingenGermany

Personalised recommendations